Literature DB >> 2513049

Prevention of blindness by screening for diabetic retinopathy: a quantitative assessment.

T E Rohan1, C D Frost, N J Wald.   

Abstract

Diabetic retinopathy is an important cause of blindness in the Western World. A review of the randomised trials of laser photocoagulation of the retina as a method of preventing blindness from this disorder showed that this treatment is very effective, reducing the risk of blindness by 61% in a treated eye. As only one eye is needed for sight the reduction in blindness in a population will be greater than 61% because the effect of treatment in one eye is not always identical with the effect in the other eye. For analysis this reduction was taken as 73%, representing the average of the minimum and maximum estimates (61% and 85%). The effectiveness of this treatment suggests that there is the potential for a national screening programme to bring about a major reduction in blindness from this cause. A quantitative assessment of the effect of screening indicated that a programme in which patients with diabetes mellitus are systematically referred to ophthalmic opticians for a retinal examination could detect 88% of all diabetics with serious retinopathy and that 87% of these cases would be treatable. Screening and early treatment of retinopathy would prevent deterioration of visual acuity and could reduce the risk of blindness due to diabetic retinopathy by an estimated 56% (0.73 X 0.88 X 0.87). The findings suggest that an effectively managed community based screening programme encompassing detection, referral, treatment, and follow up would prevent about 260 new cases of blindness in diabetics under the age of 70 each year in England and Wales. This would represent over 10% of all cases of blindness in adults in this age group.

Entities:  

Mesh:

Year:  1989        PMID: 2513049      PMCID: PMC1838060          DOI: 10.1136/bmj.299.6709.1198

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  10 in total

1.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

2.  Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three-year interim report of a randomised, controlled study using the argon laser.

Authors:  B L Hercules; I I Gayed; S B Lucas; J Jeacock
Journal:  Br J Ophthalmol       Date:  1977-09       Impact factor: 4.638

3.  Screening of diabetics for retinopathy by ophthalmic opticians.

Authors:  R S Bhopal; A J Hedley
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-25

4.  Diabetic retinopathy in the West of Scotland: its detection and prevalence, and the cost-effectiveness of a proposed screening programme.

Authors:  W S Foulds; A McCuish; T Barrie; F Green; I N Scobie; I M Ghafour; E McClure; J H Barber
Journal:  Health Bull (Edinb)       Date:  1983-11

5.  The evolution and natural history of diabetic retinopathy.

Authors:  E M Kohner
Journal:  Int Ophthalmol Clin       Date:  1978

6.  Incidence of diabetic retinopathy and blindness: a population-based study in Rochester, Minnesota.

Authors:  M S Dwyer; L J Melton; D J Ballard; P J Palumbo; J C Trautmann; C P Chu
Journal:  Diabetes Care       Date:  1985 Jul-Aug       Impact factor: 19.112

7.  Photocoagulation in diabetic retinopathy. A multicentre study in Sweden.

Authors:  S Stenkula
Journal:  Acta Ophthalmol Suppl       Date:  1984

8.  Diabetic macular edema and argon laser photocoagulation: a prospective randomized study.

Authors:  G W Blankenship
Journal:  Ophthalmology       Date:  1979-01       Impact factor: 12.079

9.  The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years.

Authors:  R Klein; B E Klein; S E Moss; M D Davis; D L DeMets
Journal:  Arch Ophthalmol       Date:  1984-04

10.  The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years.

Authors:  R Klein; B E Klein; S E Moss; M D Davis; D L DeMets
Journal:  Arch Ophthalmol       Date:  1984-04
  10 in total
  23 in total

1.  Complications of diabetes: screening for retinopathy and management of foot ulcers.

Authors:  A Melville; R Richardson; A McIntosh; C O'Keeffe; J Mason; J Peters; A Hutchinson
Journal:  Qual Health Care       Date:  2000-06

2.  A national screening programme for diabetic retinopathy. Needs to learn the lessons of existing screening programmes.

Authors:  U Freudenstein; J Verne
Journal:  BMJ       Date:  2001-07-07

3.  Purchasing good quality eye care: the provider's view.

Authors:  G Vafidis
Journal:  Qual Health Care       Date:  1997-06

4.  Diabetic retinopathy: preventing blindness in the 1990's.

Authors:  E M Kohner; M Porta
Journal:  Diabetologia       Date:  1991-11       Impact factor: 10.122

5.  Prevention of blindness by screening for diabetic retinopathy.

Authors:  R Wormald; P Courtney
Journal:  BMJ       Date:  1989-12-16

Review 6.  Impact of diabetic retinopathy screening on a British district population: case detection and blindness prevention in an evidence-based model.

Authors:  M O Bachmann; S J Nelson
Journal:  J Epidemiol Community Health       Date:  1998-01       Impact factor: 3.710

7.  Cost effectiveness analysis of screening for sight threatening diabetic eye disease.

Authors:  M James; D A Turner; D M Broadbent; J Vora; S P Harding
Journal:  BMJ       Date:  2000-06-17

8.  Loss of vision before ophthalmic referral in blind and partially sighted diabetics in Bristol.

Authors:  J B Clark; R H Grey; K K Lim; C J Burns-Cox
Journal:  Br J Ophthalmol       Date:  1994-10       Impact factor: 4.638

9.  Prompting the clinical care of non-insulin dependent (type II) diabetic patients in an inner city area: one model of community care.

Authors:  B Hurwitz; C Goodman; J Yudkin
Journal:  BMJ       Date:  1993-03-06

10.  Assessment of colour vision as a screening test for sight threatening diabetic retinopathy before loss of vision.

Authors:  G L Ong; L G Ripley; R S B Newsom; A G Casswell
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.